Predictive Factors of Analgesic Response in Patients With Pain Associated With Bone Metastasys

This is a non-profit, non-pharmacological, multicenter prospective observational study. Enrollment will last for 24 months from the opening of the study. The overall duration of the study will be 36 months. Based on the primary endpoint, patients will be stratified into 5 groups, corresponding to different times of achievement of stable pain: 1. patients who achieve stable pain at the first assessment (3 days) 2. patients who achieve stable pain at the second or third assessment (6-9 days) 3. patients who achieve stable pain at the fourth or fifth assessment (12-15 days) 4. patients who achieve stable pain at the sixth or seventh assessment (18-21 days) 5. patients who do not reach stable pain on the twenty-first day Based on the secondary endpoints, patients with and without neuropathic pain and with and without reaching PPG will be compared with the results of the HADS, EORT-QLQ-C30 \[11\] and Karnofsky scale \[12-13\] tests, in terms of final MEDD (morphine equivalent daily opioid dose) and type of drugs taken. Enrolled patients will undergo validated tests, administered by appropriately trained personnel. All the tests mentioned here are in use in clinical practice.